Leukemia, Lymphoma, & Multiple Myeloma Flashcards

1
Q

Abnormally low neutrophils is called:

A

Neutropenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Reduction in mature blood cells is called:

A

Cytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pancytopenia is a deficiency of:

A

All three cellular components (RBCs, WBCs, Platelets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Normal WBC count

A

4,400-11,000/mcL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

< 4.5K WBC

A

Leukopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

WBC >10K

A

LEUKOCYTOSIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

_________ is cancer of the body’s blood forming tissues

A

Leukemia

Effects Bone Marrow and Lymphatic System

High numbers of WBCs
• Immature cells
•Fast growth

Types:
• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Acute lymphoblastic Leukemia (ALL)
• Chronic lymphocytic Leukemia (CLL)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Most common acute leukemia in adults is:

A

Acute Myeloid Leukemia (AML)

Relatively rate even though most common leukemia

Median age ~65 years
Incidence increases with:
• Age
• M:F ratio ~5:3
• Caucasians
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Acute Myeloid Leukemia is characterized by an accumulation of ________________.

A

Leukemia blasts

Peripheral blood is ALWAYS abnormal —> biopsy

Reduced production of normal cells (neutrophils, erythrocytes, platelets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

AML Associations

A

Environmental Factors:
***Chemical exposure, radiation, tobacco, chemotherapy

Genetic abnormalities:
Trisomy 21, Fanconi’s anemia, Familial RUNX1 mutations

Malignant hematologists diseases
***Myelodysplastic syndrome (MDS), Myeloproliferative disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical presentation of AML

A

ANEMIA:
• shortness of breath
• dyspnea on exertion
• weakness/fatigue

NEUTROPENIA:
• Infection and fever related to infection

THROMBOCYTOPENIA:
• Bleeding (conjunctival hemorrhages, gingival bleeding, epistaxis, petechiae, menorrhagia, ecchymosis)

OPHTHALMIC CHANGES
• Hemorrhages or white plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AML Diagnostic tests

A

***Bone marrow aspiration and biopsy

Blasts form ≥20% of cellularity
<20% blasts in BM with cytogenetic abnormalities

CBC with diff —> cytopenia and blasts ≥ 20%

AUER RODS on peripheral smear

Elevated Creatinine and LFTs and altered electrolytes

Elevated Uric Acid and Lactate Dehydrogenase (LDH) (both from high cell turnover)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Absolute Neutrophil Count (ANC)

A

Normal = 2500-7500 (calculated as WBC x % neutrophils)

Neutrophilia (>10K) could be reactive (stress, trauma), proliferation (cancer), demargination (stress, infection), from meds (corticosteroids), from poison

Neutropenia could be from chemo, radiation, blood CA, overwhelming infection or meds (PCN)

If ANC is abnormal, RECHECK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are AUER RODS?

A

Clumps of azurophilic granule material
Form elongated needles in leukemia blasts
**Pathognomonic of myeoblasts —> AML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

AML treatment

A

Induction = chemotherapy (heavy), with goal to eradicate most leukemic cells

Consolidation = stem cell transplant, with goal to destroy remaining leukemic cells

Maintenance = lower dose chemo, supportive measures

Targeted therapies for certain mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AML prognosis

A
Favorable if:
• < 60 years old
• Good performance status
• No comorbities (ie DM, CAD)
• No Hx of exposures to cytotoxic agents or radiation 

Unfavorable if:
• Age > 60
• Hx of exposure
• Hx of myelodysplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Myelodysplastic Syndrome (MDS)

A
Cytopenia (low # blood cells)
Ineffective hematopoiesis
May be asymptomatic 
More common in those >60 (increased incidence in men, smokers, benzene exposure)
May progress to AML

Can be treatment related (chemotherapy, radiation therapy)
• Peak incidence 4-6 years after treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MDS Treatment

A

Hematopoietic growth factors help blood cells grow/mature

Immunomodulatory agents can alter or regulate immune function

Hypomethylating agents inhibit DNA methylation

Immunosuppressive therapy

Goals to Tx: Minimize cytopenias, maintain quality of life, delay onset of AML transformation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Tumor Lysis Syndrome

A

ONCOLOGIC EMERGENCY! Associated with high mortality

Massive tumor cell lysis —> release of cell contents (Potassium, phosphate, nucleic acids)

Causes:
• Initiation of cytotoxic therapy (usually within 12-24 hours of start of chemo) - possible at at treatment but esp. at first
• Spontaneously with some tumor types (high proliferation rate, large tumor burden, high sensitivity to cytotoxic therapy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The four blood manifestations of tumor lysis syndrome:

A

Hyperkalemia (inc. potassium)
Hyperphosphatemia (inc. phosphate)
Hypocalcemia (dec. calcium)
Hyperuricemia (inc uric acid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Tumor Lysis Syndrome may result in …

A

Renal failure —> hemodialysis
ECG changes (arrhythmia)
Seizure
Tetany

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment of Tumor Lysis Syndrome

A
PREVENTION!
Fluids, dieresis
Frequent monitoring during therapy (Creatinine, Potassium, Phosphorus, Uric Acid, Calcium)
Meds to lower Uric Acid
Monitor cardiac function
Seizure precautions
Treat hyperkalemia and hyperphosphatemia
Preserve renal function (dialysis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Chronic Myeloid Leukemia

A

AKA Chronic Myelogenous Leukemia

Uncontrolled production of mature and maturing granulocytes (neutophils and some basophils, eosinophils)

Abnormal gene called BCR-ABL1 fusion gene resulting from the translocation of chromosomes 9 & 22 (Philadelphia Chromosome)

15-20% of leukemia’s in adults (rare)

Slight male predominance

Median age at presentation ~50 years

Risk factor: Ionizing radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

CML signs and symptoms

A

20-50% are asymptomatic (first suspected on routine blood tests - WBC > 100K, Platelets >600K)

Fatigue (34%)
Malaise (3%)
Abdominal fullness (15%)
*Splenomegaly (48-76%)
Bleeding episodes (21%)
Pain over lower sternum (expanding bone marrow)
B symptoms
• Fever
• Weight loss 20%
• Drenching night sweats 15%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The three phases of CML are:

A

Chronic
• 85% of pats diagnosed here (often asymptomatic)
• LEUKOCYTOSIS WBC >100K
• <10% blood or BM blast cells
• Chance for remission is high if to started in this phase

Accelerated
• 10-19% blood or BM cells are blasts
• Progressively impaired neutrophil diff
• Leukocyte counts more difficult to control
• Sx - Anemia, fatigue, malaise, flu-like Sx

Blast Crisis
• Resembles acute leukemia
• 20% or more of blood or BM cells are blasts
• Sx - fatigue, fever, extramedullary blasts, splenomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Diagnosis of CML

A

Confirmed by identification of Philadelphia chromosome and/or BCR-ABL

27
Q

Treatment for CML depends on _________

A

Stage at Dx

Tyrosine Kinase Inhibitors - reduces cell communication and reproduction

Monoclonal Antibodies - Flag CA cells, trigger cell membrane destruction, block cell growth, prevent blood vessel growth, block immune system inhibitors, deliver chemo/radiation

Allogenic Stem Cell Transplant (possible cure)

Prognosis depends on phase as presentation (chronic phases = years of control, accelerated/blastic = poor prognosis), response to TKI tx, and age>65

28
Q

Complications for CML

A

Tumor lysis syndrome

HYPERLEUKOCYTOSIS - WBC >100K
• Medical emergency
• Decreased tissue perfusion, may require leukapheresis

Hyperviscosity syndrome - spontaneous bleeding from mucous membranes, visual disturbances due to retinopathy, neuro symptoms, headache, vertigo, seizures, coma
• Treat with leukapheresis (blood filter) or plasma exchange

29
Q

The most common cancer in children and teens?

A

Acute Lymphoblastic Leukemia (ALL)

About 30% of all childhood CA

Peak incidence at 2-5 years of age

M>F

Caucasians + Hispanics > African Americans

Cure rate more favorable in children

30
Q

Clinical features of ALL

A
  • Fever
  • Fatigue
  • Pallor
  • Hepatosplenomegaly (64/61%)
  • Lymphadenopathy (50%)

Other Sx: Lethargy, petechiae/ecchymosis, bone pain

Thymic mass (superior vena cava syndrome, superior mediastinal syndrome)

Testicular mass (rare, painless, unilateral)

Children: Limp, arthralgia, bleeding
Elderly: Anemia-associated dyspnea, angina, dizziness

31
Q

Lab findings for ALL

A

Lymphoblasts on peripheral blood smear
Cytopenias (neutropenia, anemia, thrombocytopenia)
Elevated LDH

Dx:
• BM biopsy

32
Q

Bone marrow biopsy findings for ALL

A

Morphology (shape)

Immunophenotype (proteins expressed by cells)
• 70-80% B precursor
• 15-17% T precursor

Cytogenics (chromosomal abnormalities)

33
Q

Different types of ALL

A

Precursor B-cell ALL
• 70-80% of all childhood cases
• 80% express CD10
• Favorable prognosis

T-cell ALL
• Standard relapse risk
• Male predominance
• Medistinal Mass
• Intramedullary disease
Mature B-cell ALL
• Also called Burkitt cell leukemia/lymphoma
• Male predominance
• Bulky extramedullary disease
• Often presents with CNS symptoms
34
Q

ALL treatment

A

Chemotherapy

Induction
• Goal to reduce tumor burden by 99%
• Restore normal hematopoiesis
• Mortality 5%

Consolidation

Maintenance

Children have 98% rate of complete response

35
Q

ALL Prognosis

A
Good —> 5-year survival >85% if:
• Age at Dx <35
• Favorable cytogenetic
• Absence of CNS disease at Dx
• B-cell v T-cell phenotype

Poor for all others

36
Q

Chronic lymphocytic leukemia (CLL) is characterized by progressive _____________________________________.

A

Accumulation of functionally incompetent B-cell lymphocytes

Most prevalent leukemia in western countries
35% of leukemia in US - adults only
Median age at dx is 70
M:F is 2:1, caucasians most affected

37
Q

Clinical Features of CLL

A

Bone Marrow failure —> anemia, thrombocytopenia, neutropenia

Organomegaly - most common finding at Dx (LAD 50-90%, Spleen 25-55%, Liver 15-25%)

Skin is the most common non-lymphoid organ affected (Leukemia cutis)

38
Q

CLL Indolent Stage

A

Most patients are asymptomatic
Lymphocytosis on blood work
B symptoms
• Unintentional weight loss ≥10% in 6 months
• Fevers >100.5 for at least 2 weeks with no infections
• Drenching night sweats
• Extreme fatigue

39
Q

Advanced Stage CLL

A
Rapidly progressive/terminal phase
May follow indolent phase
Lasts 1-2 years
Anemia 
B symptoms
Atypical infections
Death secondary to infection, bleeding, cachexia
40
Q

CLL Diagnostic Tests

A
CBC w Diff
• Absolute B lymphocytes ≥5000µL
• Mature appearing, small lymphocytes
Flow cytomegalovirus of peripheral blood
• Clonality of B lymphocytes
Bone Marrow Aspirate and biopsy
• Increased cellularity
• Lymphocytes > 30%
Lymph node biopsy
• Infiltrate-mostly mature appearing, small lymphocytes
41
Q

CLL Prognosis

A

Based on Staging (Rai and Binet systems)
• Asymptomatic early stage, median survival >10 years
• Advanced stage or progressive disease, 18 mon to 3 years survival rate without treatment

Lymphocyte doubling time
• <12 months = significantly shorter survival rate

42
Q

CLL Treatment

A

Asymptomatic early stage
• Observation - not all pt require Tx
• Localized radiation therapy

Chemotherapy

Immunotherapy
• Rituximab (CD20) and other monoclonal antibodies, used in combo with chemo

Radiation

Splenectomy

43
Q

Lymphoma is defined as cancer that begins in ______________

A

The lymphocytes

Lymphocytes located in lymph nodes, spleen, thymus, bone marrow, tonsils, adenoids

Main types = Hodgkin and Non-Hodgkin

44
Q

Risk factors for Hodgkin Lymphoma

A
Socioeconomic status 
Hx of mono caused by EBV
Immunosuppressive
Autoimmune disorders
Family Hx
45
Q

Characteristics of Hodgkin Lymphoma

A

Enlargement of lymph nodes, spleen, liver

REED-STERNBERG CELLS - Multinucleated B Cell
• Aka “Popcorn cells”

46
Q

Virus found in the Hx for 40-50% of Hodgkin Lymphoma cases

A

Epstein Barr Virus

47
Q

Key Clinical Features of HL

A

Painless LAD - cervical most common presentation

Mediastinal mass (incidental finding on CXR)

Severe pain response after alcohol

Systemic symptoms (B symptoms)
• Fever > 100.4
• Night sweats
• Weight loss

Fatigue

Pruritus without rash

48
Q

What are the B symptoms?

A

Weight loss
Fever
Night sweats

49
Q

Hodgkin Lymphoma diagnostics

A

Lymph node biopsy —> Reed Sternberg cells confirm Dx

Staging involves CT/PET of neck, chest, abdomen, pelvis

50
Q

Treatment of Hodgkin Lymphoma

A

Combination chemotherapy curative in most cases (even end-stage)

Often combined with radiation Tx (particularly in bulky disease or relapsed disease)

Stem Cell Transport - secondary relapse or persistent progressive disease

51
Q

Prognosis for HL

A

Curable in >75% of patients

Worse prognosis for those with:
• Affected lymph nodes on both sides of the diaphragm
• Bulky disease
• Distant spread

52
Q

Other considerations for Hodgkin Lymphomas

A
Secondary malignancy or recurrence of HL
CAD
Pulmonary dysfunction
Infertility
Hypothyroidism
DM
Psychosocial issues
53
Q

Non-Hodgkin Lymphoma

A

Can be derived from B or T cells (90% are derived from B lymphocytes)

Risk Factors:
• Personal or familial Hx of lymphoma
• Exposure to pesticides, hair dyes

Associations:
• Immunodeficiency *HIV)
• Autoimmune disease (Lupus, RA, Sjogren’s, Hashimoto’s)
• Inflammatory GI disease (Crohn’s, H pylori)

54
Q

Clinical Features of NonHodgkin Lymphoma

A

Painless, persistent LAD (diffuse or isolated)
Mediastinal mass in 20%
Extra lymphatic sites (GI, skin, bone, BM, abdominal fullness)
B symptoms in intermediate/high grade

55
Q

Aggressive NonHod Lymphomas

A

1/3 curable with chemo
Rapidly growing mass - mediastinal or GI
B Symptoms
Elevated LDH/uric acid

56
Q

Diagnostic studies for NHL

A

Biopsy for diagnosis/classification
• lymph nodes 2cm or > give best Dx

CT or PET/CT to learn areas of involvement and preferred biopsy site

Bone marrow aspiration and biopsy

Other options
• CSF LP
• Pleural fluid
• Peritoneal fluid
• Splenectomy
57
Q

Lugano classification for lymphomas

A

I - one node or a group of adjacent nodes
II - two or more nodal groups on the same side of diaphragm
II bulky - II with bulky disease
III - Nodes on both sides of diaphragm and with spleen involvement
IV - additional noncontiguous extralymphatic involvement

58
Q

NHL treatment

A

Based on stage of disease and patients clinical status

Indolent with 1-2 nodes = Radiation alone

Agressive intermediate or high grade —> Chemo, immunotherapy, autologous stem cell transplant

59
Q

General characteristics of Multiple Myeloma

A
Malignancy of plasma cells, proliferating in BM
• Extensive skeletal destruction
• Osteolytic lesions
• Osteopenia
• Pathologically fractures

Can form tumors —> spinal compression

Instead of making immunoglobulins, plasma cells secrete paraproteins
• Paraproteins in blood —> hyperviscosity
• Paraproteins in urine —> renal failure

60
Q

Protein electrophoresis

A

Performed on blood/urine to show paraproteins as varying narrow bands on the test strip

Demonstrates which paraproteins is present

Provides an early indication of malignant condition

Multiple Myeloma —> “M spike”

61
Q

Clinical Presentation of Multiple Myeloma

A
Fatigue (32%)
Back pain
Neurological changes (weakness in 32%, paresthesia of LE, bladder/bowel incontinence)
Bone pain (58%) esp low back, ribs
Infections
Renal Failure
Bleeding
Weight loss (24%)
62
Q

Hyperviscosity Syndrome

A

Spontaneous bleeding from mucous membranes
Visual disturbances due to retinopathy
Neurological symptoms (HA, vertigo, seizures, coma)

63
Q

Diagnostic studies for Multiple Myeloma

A
CRAB
• Calcium > 10.5
• Renal Insufficiency (Cre >2)
• Anemia (Hb <10)
• Bone Lesions

ROULEAUX formation (RBC stacks)

Hallmark: MONOCLONAL SPIKE on Protein electrophoresis (SPEP or UPEP) “M Spike”

BENCE-JONES proteins in urine

X-rays of axial skeleton —> lytic lesions, general osteoporiosis

64
Q

Treatment for Multiple Myeloma

A

Refer to hematology/oncology

Combo chemotherapy

Vertebroplasty or balloon kyphoplasty

IV BISPHOSPHONATES prevent the loss of bone mass

Autologous Hemopoeitic Cell Transplant (HCT)